Euro-Med Laboratories Phil Inc

Euro-Med Laboratories Phil Inc has a debt-to-equity ratio of 0.71 and a current ratio of 1.47, indicating moderate leverage and acceptable short-term liquidity. Free cash flow of PHP 311.4 million and operating cash flow of PHP 970.7 million suggest the company generates sufficient cash to service obligations, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity of 7.75% and return on assets of 4.22%, which are below the industry median for Pharmaceuticals, where ROE typically exceeds 10% and ROA exceeds 6%. Operating income of PHP 899.6 million and net income of PHP 470.3 million reflect a net margin of 6.85%, which is in line with the sector’s lower end. The company’s revenue is concentrated across three segments: pharmaceutical manufacturing, healthcare services, and quick service restaurants. The pharmaceutical segment is the largest contributor, though the QSR segment, through subsidiary CafeFrance, adds diversification. No geographic breakdown is available, but the Philippines is the primary market. Outlook for the current fiscal year shows stable revenue growth, with a projected increase of 2.5% year-over-year. Capital expenditure of PHP -269.9 million indicates a reduction in investment, likely due to asset optimization or maintenance. The next fiscal year is expected to see a 1.8% revenue contraction, driven by market saturation in core pharmaceutical products. Risk assessment highlights medium liquidity risk due to negative net cash and a debt load of PHP 4.3 billion. Dilution risk is low, with no near-term pressure from share issuance or ATM programs. However, the company’s reliance on a narrow product portfolio and exposure to healthcare regulatory shifts pose medium-term challenges. Recent filings and transcripts indicate a focus on cost optimization and expansion of dialysis services through Hemotek. No major legal or operational disruptions were disclosed in the latest 10-K equivalent.